Groundbreaking accordion effect makes graphene more stretchable by removing atoms
Austrian researchers have unlocked a groundbreaking property of graphene, making it significantly more stretchable by manipulating its structure to ripple like an accordion using a one-of-a-kind method that has never been seen before.
The unique technique, pioneered by scientists at the University of Vienna and the Vienna University of Technology, involved the meticulous manipulation of the atomic structure of graphene, a material extracted from graphite and is made up of pure carbon, in an ultra-clean, airless environment.
This unique setup ensured that the graphene samples remained free from ambient air and foreign particles, which could interfere with the measurements and distort the results.
Jani Kotakoski, PhD, a physics professor at the University of Wien and lead author of the research, believes the discovery opens up exciting new possibilities for the material, enabling its use in applications requiring enhanced flexibility, such as wearable electronics and advanced flexible devices.
In 2004, the discovery of graphene by researchers Andre Geim, PhD, and Kostya Novoselov, PhD, from the University of Manchester, revolutionized science, introducing a new class of materials known as two-dimensional (2D) solids.
These materials, just a single atom thick, possess unique properties that hold significant promise for various applications, with graphene being particularly celebrated for its exceptional electrical conductivity, flexibility, lightness and high resistance.
However, its extreme stiffness, a result of its honeycomb-shaped arrangement of the atoms, has limited its use in many applications. Although removing atoms from its structure might be expected to reduce its stiffness, studies have yielded mixed results, with some research suggesting a slight decrease in rigidity, while others show an increase in stiffness.
Now, to address the issue, the research team conducted experiments in an ultra-clean, airless environment, using state-of-the-art equipment to ensure that the graphene samples were completely isolated from external air and contaminants. The controlled setup allowed researchers to carry out precise measurements, eliminating interference from airborne particles that might have affected the accuracy of the results.
"This unique system we have developed in the University of Vienna allows us to examine 2D materials without interference," Kotakoski explained. "For the first time this kind of experiment has been carried out with the graphene fully isolated from ambient air and the foreign particles it contains. Without this separation, these particles would quickly settle on the surface affecting the experiment procedure and measurements."
According to Kotakoski, the breakthrough came from an intense focus on keeping the graphene surface completely clean during testing. The researchers discovered that removing just two neighboring atoms from the otherwise flat material caused it to bulge slightly.
As more of these small bulges formed, they created a corrugated, wave-like structure, which the scientists have called the 'accordion effect.'
"You can imagine it like an accordion," Joudi explained in a press release. "When pulled apart, the waved material now gets flattened, which requires much less force than stretching the flat material and therefore it becomes more stretchable."
The findings were further backed by computer simulations from theoretical physicists Rika Saskia Windisch, MSc, and Florian Libisch, PhD, at the Vienna University of Technology, which confirmed the formation of these atomic ripples and the resulting increase in flexibility.
The experiments also revealed that contamination from foreign particles on the material's surface completely suppresses the accordion effect. In fact, their presence can make the material seem stiffer, providing a likely explanation for conflicting data in earlier studies.
"This shows the importance of the measurement environment when dealing with 2D materials," Joudi concluded. "The results open up a way to regulate the stiffness of graphene and thus pave the way for potential applications."
The study has been published in the journal Physical Review Letters.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Self-Driving Truck Startup Plus Goes Public In $1.2B SPAC Merger, Backed By Wall Street Titan Michael Klein And Hyundai
Plus Automation last week it would merge with special purpose acquisition company Churchill Capital Corp IX (NASDAQ:CCIX) that values the startup at $1.2 billion and brings $300 million in fresh capital for its push into autonomous trucking by 2027. According to Plus Automation, the merger provides the resources needed to scale its factory-integrated autonomous trucking model. After closing, the combined company will operate as PlusAI and prioritize deployment through its global original equipment manufacturer partnerships. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Inspired by Uber and Airbnb – Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets – Plus Automation is led by a founding team of Stanford-trained PhD engineers and seasoned tech entrepreneurs, each with a history of building and scaling innovation-focused companies. CEO David Liu, now on his fourth startup, brings a consistent track record of growth across prior ventures, reinforcing investor confidence in the company's ability to execute, Plus Automation says. Launched in 2016 from Silicon Valley, Plus Automation designed SuperDrive as an AI-based virtual driver for heavy-duty trucks. The company says that its system has already accumulated more than 5 million miles across the U.S., Europe, and Asia, forming a robust real-world dataset that underpins its neural-network engine. In April, SuperDrive hit a crucial driver-out safety milestone, signaling readiness for commercial deployment. According to Plus Automation, public road trials are active in Texas and Sweden, with broader fleet testing slated for fall. Trending: Invest where it hurts — and help millions heal:. Plus Automation's strategy leans heavily on factory integration rather than retrofitting existing trucks. That original equipment manufacturer-first model involves close collaboration with Hyundai, TRATON Group, and Iveco to produce SuperDrive-enabled trucks at scale, Plus Automation says. Churchill Capital Corp IX, led by veteran financier Michael Klein, will provide up to $300 million from its trust account to finance Plus Automation's next growth phase. Plus Automation says that this injection is expected to fully fund the startup through its 2027 commercial launch without requiring additional equity raises. The merger maintains a clean balance sheet for the combined entity and locks up existing Plus Automation shareholders for 180 to 360 days to reinforce long-term commitment. Plus Automation and its and Churchill IX's shareholders will hold one-vote shares to ensure governance European and U.S. trucking markets are valued at nearly $2 trillion, facing persistent shortages of around 300,000 drivers annually, the company says. Plus Automation plans to monetize via a per-mile "driver-as-a-service" model to generate high-margin recurring revenue. Physical AI solutions are gaining traction due to lighter regulations and growing demand for logistical efficiency. Dealer interest is rising as governments across the U.S. consider easing safety rules for heavy autonomous vehicles. California's Department of Motor Vehicles recently proposed testing heavy-duty self-driving trucks on public roads, marking an important regulatory shift. Closing is expected in the fourth quarter, pending shareholder approvals, Plus Automation says. Read Next: Here's what Americans think you need to be considered wealthy. Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can Image: Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Self-Driving Truck Startup Plus Goes Public In $1.2B SPAC Merger, Backed By Wall Street Titan Michael Klein And Hyundai originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Medscape
2 hours ago
- Medscape
MRD: A Shared Compass for Patients, Clinicians, and Regulators
MILAN — The landscape of hematologic malignancies is shifting rapidly, in part due to the evolving significance of measurable (formerly "minimal") residual disease (MRD). Once confined to the realm of research, MRD is emerging as a critical tool for clinical and regulatory decision-making. In conditions such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and multiple myeloma (MM), MRD has become more than a marker of extent of disease burden; it now informs prognosis, therapeutic response, and access to novel treatments. "MRD is not a new concept; it has been studied for years", Jesus San Miguel Izquierdo, MD, PhD, director of clinical and translational medicine at the University of Navarra, Pamplona, Spain, told Medscape Medical News . Thanks to technological advances, unprecedented sensitivity in detecting residual cancer cells following treatment, in other words MRD, has been achieved. "We are capable of identifying a single tumor cell among a million," said San Miguel Izquierdo, who was awarded the 2025 EHA Lifetime Achievement Award for his lifelong work in MM. At a multidisciplinary session here at the European Hematology Association (EHA) 2025 Annual Meeting in Milan, representatives of patient organizations, clinicians, and regulatory bodies offered insights into the expanding role of MRD. Although its utility as an indicator of treatment response is widely recognized, debates remain over standardization, regulatory implications, and its intersection with patient experience and access. The Patient Voice: MRD as a Tool of Hope and Anxiety Anne-Pierre Pickaert, a survivor of ALL and patient advocate, described MRD in profoundly personal terms. For many patients, MRD is both a beacon and a burden. "It's like a needle in a haystack," she explained, noting that the absence of detectable cancer cells does not always equate to the absence of disease, and that uncertainty can be emotionally taxing. The terminology shift from "minimal" to "measurable" residual disease may have technical sense, but it can be unsettling for patients. "Minimal" is often interpreted as benign or reassuring, whereas "measurable" conveys clinical precision but may also amplify anxiety. Conversely, "minimal" can offer false reassurance, underestimating actual risk. There are also disparities in how MRD is communicated and understood across different hematologic diseases. For patients with ALL or AML, MRD status can dictate eligibility for transplants, trials, or access to novel therapies. In contrast, patients with chronic lymphocytic leukemia or lymphoma may be less familiar with the concept, reflecting its inconsistent use in routine care. Advocacy networks face challenges in delivering cohesive education across this diverse landscape. Pickaert also used the term "MRD-xiety," likening it to the "scanxiety" experienced by patients with solid tumors awaiting imaging results. As MRD often determines treatment direction, it carries substantial emotional weight. Yet most patients remain unaware of the regulatory frameworks that shape access to MRD-guided interventions. "We just want access," she said, be it through compassionate use, early access programs, or full reimbursement. Clinician Perspective: A Shift in Therapeutic Strategy Nicola Gökbuget, MD, head of the study center, department of hematology/oncology, University Cancer Center, Frankfurt, Germany, highlighted how MRD is transforming clinical strategy. Presenting an ALL case, she emphasized the paradigm shift from hematologic to molecular decision-making. "Historically, we acted on clinical relapse. Today, persistent or re-emerging MRD — as a molecular failure — can prompt therapeutic changes." This proactive model is influencing clinical trial designs and enabling more personalized approaches, such as targeting residual disease before transplant. In contrast, classical strategies relied on hematologic response and salvage therapy after hematologic progression. Still, the clinical utility of MRD depends on standardization. Clinicians need consensus definitions for response categories — complete molecular remission, intermediate response, molecular failure — as well as harmonized testing modalities and timepoints. Gökbuget stressed that the value of MRD risks being undermined without unified standards. Coordinated efforts from academic groups and industry partners will be essential. The Regulatory View: Is Surrogacy the Right Goal? Pierre Démolis, MD, PhD, chair of the Oncology Working Party and co-chair of the Scientific Advice Working Party at the European Medicines Agency, discussed the nuanced regulatory stance on MRD. Although MRD is a powerful indicator of response, it is not yet a validated surrogate endpoint. Surrogacy, in regulatory terms, requires consistent, reproducible correlation with overall survival across various contexts; something MRD has not fully achieved. Still, Démolis advocates for MRD as a "response trigger" in adaptive designs, transplant decisions, and early treatment assessments. "Let's stop pretending surrogacy is required to make MRD useful," he said. "It's like objective response rate or complete hematologic response; we've used such endpoints for decades." He clarified the distinction between activity and efficacy: activity refers to pharmacodynamic effects (eg, tumor shrinkage, MRD negativity), while efficacy denotes clinical benefit (eg, overall survival, progression-free survival). Activity-based endpoints such as MRD are already used in single-arm trials, particularly when randomized data are impractical. However, MRD should not replace overall survival as the final endpoint. "It can be used in conditional settings, provided final efficacy outcomes confirm its relevance," he added. Survey Shows Divergence in Attitudes Anna Smit, a PhD candidate at Erasmus MC Cancer Institute in Rotterdam, the Netherlands, presented preliminary findings from a joint EHA-International Myeloma Society survey on the role of MRD in MM trials. Among 389 healthcare professionals and 40 regulators surveyed, most supported MRD negativity as a primary endpoint, regardless of transplant eligibility. Nearly all respondents emphasized the need for global standardization. Yet variation in techniques and sensitivities remains a major barrier. Smit noted that in April 2024, the Oncologic Drugs Advisory Committee of the US Food and Drug Administration unanimously supported MRD-negative complete response as an endpoint to justify accelerated approval in MM. Europe, however, has not yet agreed to this and continues to monitor the field. Démolis confirmed ongoing global regulatory discussions on different topics, including MRD, highlighting monthly exchanges among agencies to share and possibly align perspectives. Patient-Centered Medicine Remains Paramount Quality of life (QoL) was also discussed during the session as another important aspect of the patient-centered approach to hematologic malignancies. For Pickaert, QoL is a non-negotiable endpoint: "Patients want survival, but not at any cost." Démolis echoed this view: "If you prolong life by a month but destroy QoL, is that meaningful?" Gökbuget acknowledged the practical difficulties of collecting QoL data, especially in acutely ill populations, but emphasized that such hurdles are not insurmountable. "Even when patients are unwell, someone can help complete the questionnaire," Pickaert said. Integrating QoL into MRD-based strategies could ensure that treatments extend not just life but also well-being. "As regulators, we must prioritize QoL in our decisions," Démolis said. San Miguel Izquierdo reinforced this message in a comment to Medscape Medical News . "Looking at MRD allows for early intervention," he said, implicitly linking early intervention to better QoL. Although some clinicians worry about overtreatment, the risk of undertreatment is often far greater. "By ignoring MRD, we risk undertreating 90% of patients and overtreating 10%," he concluded. Pickaert, Smit, and Démolis have reported no relevant financial relationships. Gökbuget has reported advisory board participation for and speaker honoraria and travel support from Amgen, AstraZeneca, Autolus, Celgene, Clinigen, Gilead, Incyte, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi, and Servier; and institutional research support from Amgen, Clinigen, Incyte, Jazz Pharmaceuticals, Novartis, and Servier. San Miguel Izquierdo has declared participation on advisory boards and consulting services, on behalf of his institution, for AbbVie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, Secura Bio, and Gilead-Kite.
Entrepreneur
2 hours ago
- Entrepreneur
Entrepreneur UK's London 100: Spruce
Industry: Supply Chain Sustainability Spruce is a London-based API startup tackling sustainability at the source – within the supply chain. Founded by Oxford alumni Louis and Maximilian, Spruce shifts focus from high-level carbon dashboards to helping suppliers, especially SMEs, report accurate, product-level sustainability data directly from invoices and logistics records. This data flows into enterprise procurement systems, enabling buyers to verify carbon, material, and social metrics without relying on estimates, PDFs, or manual follow-ups. With regulations like CSRD, Scope 3, and Digital Product Passport rules approaching, companies need real, auditable data to back their sustainability claims. Spruce provides the infrastructure to make that possible. A global CPG company is already onboarding over 500 suppliers, with strong traction via integrations into existing procurement tools. What sets Spruce apart is its pragmatic approach – suppliers don't need to be ESG experts. Spruce automates data collection, applies intelligent rules to highlight gaps, and makes compliance seamless. Backed by the Oxford Seed Fund, climate-focused angels, and early-stage VCs, Spruce has raised its seed round to expand its technical team and scale enterprise partnerships, paving the way for more transparent and efficient sustainability reporting.
